Zelos Receives Regulatory Approval for Phase III Osteoporosis Trial
Posted on: Friday, 25 July 2008, 12:01 CDT
Zelos Therapeutics has signed agreements with the FDA and the European Medicines Agency for a Phase III registration study of ZT-031 for the treatment of severe osteoporosis.
Following the special clinical protocol assessment process with the FDA and a formal scientific advice meeting with the Committee for Human Medicinal Products of the European Medicines Agency (EMEA), Zelos Therapeutics has received regulatory approval for the design, conduct and analysis of a pivotal Phase III clinical study.
The trial, if successful, would form the primary basis for an efficacy claim to support applications for marketing authorization of ZT-031 in the US and Europe.
The 24-month Phase III study is expected to enroll 3,255 post-menopausal women with severe osteoporosis. The primary efficacy endpoint is the incidence of new vertebral fractures in the ZT-031 study arm compared with the alendronate study arm.
In addition, the FDA and EMEA have agreed to an innovative weight-based dosing regimen in which different dose strengths of ZT-031 will be used in patients in different weight categories.
Zelos Therapeutics believes that the safety and efficacy profile of ZT-031 that has been demonstrated to date, coupled with the anticipated improvements in clinical benefit that may result from weight-based dosing, could position ZT-031 favorably against Forteo (teriparatide), the only bone formation therapeutic currently approved for use in the US.
Source: Datamonitor
Related Articles
- Greer Completes Enrollment for Pivotal Phase III Clinical Trial Evaluating the Efficacy of Sublingual-Oral Immunotherapy for Treating Short Ragweed Allergies
- Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate Its Diclofenac Patch for Mild to Moderate Pain
- Elixir Pharmaceuticals Initiates Final Phase III Clinical Study Prior to NDA
- ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From Its U.S. Phase II/III Clinical Study Of Bepotastine
- Eurand Announces Positive Phase III Clinical Study Results
- Jazz Pharmaceuticals Announces Phase III Clinical Trial to Study the Safety and Efficacy of Xyrem(R) (Sodium Oxybate) in Patients With Fibromyalgia Syndrome
- Cobalis Provides Update on Clinical Program For PreHistin(R); Announces Study Design Involving Twin Phase III Clinical Trials
- ADVENTRX Receives FDA Clearance Under a Special Protocol Assessment to Initiate CoFactor Phase III Clinical Trial
- deCODE Announces Special Protocol Assessment Agreement With the FDA for Phase III Clinical Trials of DG031
- Kyowa Releases Results to Phase III Clinical Studies of an Anti-Parkinson's Disease Drug Istradefylline (KW-6002) Conducted Overseas
User Comments (0)
RSS Feeds